Adjunctive Glycine for Obsessive Compulsive Disorder

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00405535

Enrollment

Registered

2006-11-30

Start date

2004-06-30

Completion date

2006-12-31

Last updated

2016-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive Compulsive Disorder

Keywords

OCD, Obsessive Compulsive Disorder, Glycine

Brief summary

The purpose of this study is to determine whether individuals with obsessive compulsive disorder who will take a preparation of the amino acid glycine in addition to their current treatment, may experience improvement in their symptoms.

Detailed description

Individuals with obsessive compulsive disorder (OCD) often find inadequate relief, even with the best of currently available treatments. Some evidence suggests the the neurotransmitter glutamate may be a useful target for new treatments for OCD. The amino acid glycine, if given orally in adequate dosages, can have specific effects on one particular glutamate receptor molecule in the brain, that might be helpful with OC symptoms. This randomized, double-blind protocol will have study participants who suffer with OCD take either a glycine preparation or placebo for 12 weeks. Clinical measures (e.g., Y-BOCS, NIMH-OC) will be recorded at each visit to determine whether those taking the glycine experience clinical benefit.

Interventions

DRUGglycine

OTHERplacebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of OCD present for at least 1 year * Male or female, age 18 to 65 * Stable medication regimen for 12 weeks prior to study entry * at least moderately severe OC symptoms

Exclusion criteria

* Active substance use disorder within the last 6 months * Comorbid schizophrenia, schizoaffective disorder, bipolar disorder, tic disorder, Tourette Disorder, schizotypal personality disorder * Hoarding as the principal OCD symptom * Insulin-dependent diabetes mellitus * Pregnant or breastfeeding

Design outcomes

Primary

Measure	Time frame
Y-BOCS (Yale-Brown Obsessive Compulsive Scale)	12 weeks after baseline

Secondary

Measure	Time frame
NIMC-OC scale	12 weeks after baseline
CGI-Improvement	12 weeks after baseline
QLS(Quality of Life Scale)	12 weeks after baseline
Sheehan Disability Scale	12 weeks after baseline

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 4, 2026